Type 2 DM (57%) and prevention or disease-management programs (54%). In average, models had 11 states and 2.8 complications. MC were signifi cantly more used than Markov when both type 1 and 2 DM and a prevention or disease management program were concerned. Models had, signifi cantly, a higher number of states and complications. The choice of the model type was shown to be infl uenced by the number of DM and of complications considered. The justifi cation to perform a Monte-Carlo was more often documented than those to perform a Markov (74% vs. 38%). The model was considered accurate with the study question in respectively 86% of Monte-Carlo and 64% of Markov. CONCLUSIONS: This study allowed to statistically identify factors infl uencing the type of model used to simulate DM. It is an interesting tool for modelers in their decision process to build a model. Information such as data and time availability or fi nancial context could not be collected.
1
Takeda Pharmaceuticals International, Inc., Deerfi eld, IL, USA; 2 Boston University of School of Medicine, Boston, MA, USA OBJECTIVES: While the comorbidity burden of gout in the US has been considered substantial and may have been rising over the past decade, no contemporary national data are available. We estimated the prevalence of major comorbidities in patients with gout compared with those without gout based on a recent, nationally representative sample of US men and women (National Health and Nutrition Examination Survey [NHANES] 2007 [NHANES] -2008 . METHODS: Using data from 5707 participants in NHANES 2007 NHANES -2008 NHANES (2797 NHANES men and 2910 aged 20 years and older, we determined the prevalence of major comorbidities among individuals with gout, including hypertension, renal impairment, nephrolithiasis, diabetes, myocardial infarction, heart failure, stroke, and obesity. We also compared the prevalence with those without gout using age-and sex-adjusted logistic regressions. Case defi nitions of comorbidities were based on an affi rmative answer to a question asking if a physician or a health professional had diagnosed the corresponding condition. RESULTS: Among US adults with gout, 74% had hypertension, 53% obesity, 26% diabetes, 24% nephrolithiasis, 14% myocardial infarction, 11% heart failure, 10% stroke, and 9% renal impairment (Table) . Prevalence of these comorbidities among individuals with gout was substantially higher than among individuals without gout. Age-and sexadjusted odds ratios (95% confi dence interval [CI]) were 4.19 (2.75-6.39) for hypertension, 2.35 (1-55-3.57) for obesity, 2.36 (1.49-3.73) for diabetes, 2.10 (1.39-3.18) for nephrolithiasis, 2.37 (1.54-3.65) for myocardial infarction, 2.68 (1.88-3.83) for heart failure, 2.02 (0.98 to 4.19) for stroke, and 3.50 (2.05-5.98) for renal impairment. CONCLUSIONS: These fi ndings from the latest nationally representative sample of US adults in NHANES 2007-2008 confi rm that the prevalence of comorbidities among individuals with gout is substantial and considerably higher than among individuals without gout.
PMS2 DISABILITY OUTCOMES AND DOSE ESCALATION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR BLOCKERS: A COMPARATIVE EFFECTIVENESS ANALYSIS
Schabert VF 1 , Bruce B 2 , Ferrufi no CP 1 , Fries JF 2 , Globe D 3 , Harrison DJ 3 1 IMS Health, Falls Church, VA, USA; 2 Stanford University, Division of Immunology & Rheumatology, Palo Alto, CA, USA; 3 Amgen Inc., Thousand Oaks, CA, USA OBJECTIVES: Previous cohort studies using US commercial insurance claims of rheumatoid arthritis (RA) patients have observed higher dose escalation rates for patients treated with tumor necrosis factor-α (TNF) blockers infl iximab (INF) or adalimumab (ADA) than for etanercept (ETN). However, such databases cannot be used to determine whether dose escalation is associated with improved clinical outcomes. We compared functional disability and dosing history between patients treated with TNF blockers using data from a large, prospective observational registry (Arthritis, Rheumatism, and Aging Medical Information System; ARAMIS) of RA patients in the US. METHODS: ARAMIS enrolled adult physician-diagnosed RA patients. Patients who met following inclusion criteria were selected: treated with a TNF blocker for ≥9 months; had no biologics 6 months before index TNF treatment; and reported a Health Assessment Questionnaire Disability Index (HAQ-DI) at index and 9-15 months after index. Self-reported dosing information was validated by telephone follow-up, medical, billing, or retail pharmacy prescription records. Dose escalation was defi ned as dosing above fi rst ADA/ETN or third INF dose. Multivariate models compared HAQ-DI change and dose escalation rates, controlling for variables that differed among INF, ADA and ETN patients at index. RESULTS: Approximately 351 patients (93 INF, 40 ADA, 218 ETN) met study criteria. Subjects were mostly female (83%), Caucasian (88%), and had mean disease duration of 18.9 years. HAQ-DI change scores at 9-15 months did not differ by treatment (−0.10, −0.08, and −0.12 points for INF, ADA, and ETN, respectively; P = 0.52). Dose increases were observed in 1.4% of ETN patients, as compared with 10.8% of INF (P < 0.001) and 12.5% of ADA patients (P = 0.004, both vs. ETN). HAQ-DI change was associated with pre-index HAQ-DI score and disease duration (both P < 0.05). CONCLUSIONS: This study showed dose escalation in fewer ETN than INF or ADA patients, but similar improvements in functional disability.
PMS3 IMPROVEMENT IN EFFICACY AND SAFETY OUTCOMES AFTER CERVICAL ARTHROPLASTY VERSUS STANDARD ANTERIOR CERVICAL DISECTOMY AND FUSION (ACDF) SURGERIES: A META-ANALYSIS OF PUBLISHED RCTS
Gill S 1 , Maetzel A 2 , Alvares L 3 , Birinyi-Strachan L 3 1 Frenchay Hospital, Bristol, UK; 2 Stratas Partners, Basel, ON, Switzerland; 3 Medtronic International Trading Sàrl, Tolochenaz, VD, Switzerland BACKGROUND: Cervical arthroplasty has been used successfully worldwide for over a decade in patients with cervical degenerative disc disease (CDDD). Several RCTs have documented the clinical advantage of arthroplasty vs. fusion for this patient population. Synthesis of outcomes from published RCTs is needed to consolidate the evidence-base for arthroplasty in CDDD. OBJECTIVES: To examine current evidence of safety and effi cacy in the use of arthroplasty to treat CDDD and conduct a pooled analysis of high level comparative outcomes for arthroplasty versus fusion. METHODS: A systematic search of the PubMed, EMBASE, MEDLINE, CRD York, and Cochrane Library databases, plus hand searching of grey literature was undertaken in January 2010. RESULTS: A total of 554 non-duplicate citations were retrieved. Only three studies of arthroplasty versus fusion with 2 years follow-up met all inclusion criteria and were of reasonable quality (according to GRADE criteria) to pool. a meta-analysis was conducted using RevMan5 software (Cochrane 2008). Persons undergoing single-level arthroplasty had signifi cantly improved neurological success (RR 1.14, 95% CI [1.07, 1.21] P < 0.0001), Neck Disability Index (NDI) success (RR 1.13, 95% CI [1.05, 1.22] P = 0.001) and overall success (RR 1.22 95% CI [1.12, 1.33], P < 0.00001) at 2 years post surgery compared to fusion. Secondary surgeries (any revision, removal, or re-operation of the implant or supplemental fi xation) after 2 years were also signifi cantly lower with arthroplasty (13/621) compared to fusion (39/592), [0.32 95% CI [0.17, 0.59) P = 0.0003]. Total number of patients undergoing reoperations at adjacent levels was lower in arthroplasty-treated patients (9/621) vs. ACDF (17/592), however it was not statistically signifi cant (P = 0.09). Given the small numbers of patients undergoing reoperations at adjacent levels, longer term results are needed to increase precision of this estimate. CONCLUSIONS: A formal pooled analysis of 2-year RCT data demonstrates clinically signifi cant improvements in effi cacy and safety outcomes in CDDD patients who have undergone arthroplasty versus standard fusion. 
PMS4 NUMBER NEEDED TO TREAT FOR PATIENTS TO REPORT BROAD RELIEF FROM THE BURDEN OF RHEUMATOID ARTHRITIS WHEN TREATED WITH CERTOLIZUMAB PEGOL PLUS METHOTREXATE

